干细胞治疗视网膜疾病:前景与风险的视角
本文以解释性论述形式综述干细胞/祖细胞干预视网膜疾病(如年龄相关性黄斑变性和遗传性视网膜营养不良)的早期安全性和有效性信号。部分早期临床试验提示安全性可接受,但涉及某些自体非眼源性细胞类型的报告与严重致盲并发症相关;目前尚无美国食品药品监督管理局批准的干细胞疗法用于视网膜疾病。
要点
- 干细胞/祖细胞干预是视网膜疾病的新型潜在疗法,来源包括多能干细胞及胎儿和出生后组织。
- 提出「救援」机制包括再生性或营养性两类。
- 部分早期试验提示安全性可接受,但某些自体非眼源性细胞干预与严重致盲并发症相关。
核心结论
- 干细胞/祖细胞干预有潜力解决影响全球数亿人的致盲性视网膜疾病,但目前尚无美国食品药品监督管理局批准的干细胞疗法用于视网膜疾病。
- 尽管部分早期试验数据有前景,但细胞干预致盲并发症的报告仍令人担忧。
- 至关重要的是对精心规划、分步进行的临床前和临床研究序列应用高水平的科学严谨性,以确定这类潜在疗法对视网膜疾病患者是否安全和有效。
研究设计与样本
- 解释性论述,对选定的近期干细胞/祖细胞干预视网膜疾病报告进行综述与整合,并给出解读和视角。
主要发现
- 干细胞/祖细胞干预是视网膜疾病(如年龄相关性黄斑变性和遗传性视网膜营养不良等)的新型潜在疗法,来源包括多能干细胞及胎儿和出生后组织。
- 已提出两种「救援」机制:再生性或营养性。
- 多能干细胞和胎儿来源细胞类型已在视网膜疾病临床前动物模型中测试,但许多目前进入试验的出生后干细胞/祖细胞群体缺乏临床前安全性或有效性数据。
- 部分细胞疗法早期试验提示安全性可接受;另一些涉及某些自体非眼源性细胞来源的报告与严重致盲并发症相关。
- 需要更大规模的试验来确定这些细胞干预的短期和长期安全性与有效性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 许多目前进入试验的出生后干细胞/祖细胞群体缺乏临床前安全性或有效性数据。
- 需要更大规模的试验来确定这些细胞干预的短期和长期安全性与有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To summarize key concepts, as well as early safety and efficacy signals from clinical trials, for stem/progenitor cell-based interventions for retinal disease. DESIGN: Interpretive essay. METHODS: Review and synthesis of selected recent reports of stem/progenitor cell-based approaches for retinal disease, with interpretation and perspective. RESULTS: Stem/progenitor cell-based interventions represent a novel class of potential therapies for retinal diseases, such as age-related macular degeneration and inherited retinal dystrophies, aoong others. Sources include pluripotent stem cells and fetal and postnatal tissues. Two mechanisms of "rescue" have been proposed: regenerative or trophic. Although pluripotent and fetal sourced-cell types have been tested in preclinical animal models of retinal disease, many postnatal stem/progenitor cell populations currently in trial do not have preclinical safety or efficacy data. Some early-phase trials of cell therapies suggest acceptable safety profiles. Other reports, involving some types of autologous, nonocular cell sources, have been linked to severe, blinding complications. Larger trials will be needed to determine short-term and long-term safety and efficacy of these cell-based interventions. CONCLUSIONS: Stem/progenitor cell-based interventions have the potential to address blinding retinal diseases that affect hundreds of millions worldwide. Yet no Food and Drug Administration-approved stem cell therapies for retinal disease exist. Although some early-phase trial data are promising, reports of blinding complications from cell interventions remain troubling. It is paramount to apply a strong level of scientific rigor toward a well-planned, step-wise sequence of preclinical and clinical studies, to determine whether this class of potential therapies will be safe and effective for individuals with retinal diseases.
引用
- Rao RC, Dedania VS, Johnson MW, et al. Stem Cells for Retinal Disease: A Perspective on the Promise and Perils. Am J Ophthalmol. 2017. PMID: 28428049. doi:10.1016/j.ajo.2017.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。